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BACKGROUND:This study aimed to evaluate the safety and efficacy of dose-dense weekly chemotherapy, followed by resection and/or
thoracic radiotherapy.
METHODS: Patients with histologically documented thymoma with unresectable stage III disease received 9 weeks of chemotherapy:
cisplatin 25mgm
 2 on weeks 1–9; vincristine 1mgm
 2 on weeks 1, 2, 4, 6 and 8; and doxorubicin 40mgm
 2 and etoposide
80mgm
 2 on days 1–3 of weeks 1, 3, 5, 7 and 9. Patients went on to surgery and post-operative radiotherapy of 48Gy; those with
unresectable disease received 60Gy radiotherapy.
RESULTS: A total of 23 patients were entered. The main toxicities of the chemotherapy regimen were neutropenia and anaemia, and
57% of patients completed the planned 9 weeks of therapy. There were no toxic deaths. Of the 21 eligible patients, 13 (62%)
achieved a partial response (95% confidence interval: 38–82%). Thirteen patients underwent a thoracotomy and nine (39%)
underwent complete resection. Progression-free survival at 2 and 5 years was 80 and 43%, respectively. Overall survival at 5 and
8 years was 85 and 69%, respectively. Survival did not seem to be affected by resection.
CONCLUSION: In thymoma patients, weekly dose-dense chemotherapy has activity similar to that of conventional regimens. Although
some patients could achieve complete resection, the role of surgery remains unclear.
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Thymoma is one of the most common tumours to originate in the
mediastinum (Giaccone, 2005; Girard et al, 2009). Although its
clinical behaviour tends to be indolent, it eventually disseminates
into the pleural space or sometimes leads to distant metastases.
Masaoka’s classification has been widely used for clinical staging
(Masaoka et al, 1981; Girard et al, 2009).
The majority of thymomas are discovered at a limited stage,
Masaoka’s stage I or II, and surgical resection is the treatment of
choice for such cases (Giaccone, 2005; Girard et al, 2009). Even
when the tumour invades neighbouring organs, namely, stage III
disease, surgical resection with post-operative radiotherapy is the
preferred treatment when the tumour can be completely resected
(Curran et al, 1988; Urgesi et al, 1990; Ogawa et al, 2002; Strobel
et al, 2004).
However, for stage III, unresectable tumours, a combination
of chemotherapy and radiotherapy with or without surgical
resection is frequently used, but optimal management remains
controversial (Ciernik et al, 1994; Loehrer et al, 1997; Kim et al,
2004; Mangi et al, 2005; Lucchi et al, 2006). There are very few
prospective trials with limited numbers of cases, some including
stage IV cases (Loehrer et al, 1997; Kim et al, 2004; Girard et al,
2009).
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chemotherapy-sensitive tumours, with a response rate of 50–70%
to combination chemotherapy (Loehrer et al, 1994, 1997, 2001;
Giaccone et al, 1996; Berruti et al, 1999; Kim et al, 2004; Lucchi
et al, 2006; Yokoi et al, 2007). Active agents include cisplatin
(CDDP), vincristine (VCR), doxorubicin (ADM), etoposide (ETP),
cyclophosphamide (CPM) and ifosfamide (IFX).
Dose-dense chemotherapy with the CODE combination
(CDDP–VCR–ADM–ETP), combined with granulocyte colony-
stimulating factor (G-CSF), has been shown to be safe when
administered to patients with advanced lung cancer (Murray et al,
1991; Fukuoka et al, 1997). Theoretically, it might be suitable for
chemo-sensitive tumours such as small-cell lung cancers and
thymomas, especially in cases with limited tumour burden (Goldie
and Coldman, 1983; Levin and Hryniuk, 1987; Murray, 1987).
Because of the pilot data in Japan that had suggested that
administration of 12 weeks of CODE chemotherapy was barely
feasible, subsequent Japanese trials used a modified schedule
that was shortened to 9 weeks (Fukuoka et al, 1997; Furuse et al,
1998).
In 1996, we, the Japan Clinical Oncology Group (JCOG),
initiated two clinical trials for advanced thymoma: one aimed
to evaluate the safety and efficacy of the CODE regimen in
stage IV, disseminated thymoma (JCOG 9605), and the other
aimed to evaluate the safety and efficacy of CODE combination
chemotherapy, followed by surgical resection and post-operative
radiotherapy, in initially unresectable stage III thymoma
(JCOG 9606). The primary end point in each study was
progression-free survival (PFS). The results of JCOG 9606 are
reported herein.
PATIENTS AND METHODS
Eligibility criteria
Patients with previously untreated, histologically documented
thymomas with Masaoka’s stage III disease that was judged to be
unresectable by the surgeons, radiologists and medical oncologists
at each institute were eligible for entry. Thymoma had to be
confirmed histologically, and thymic tumours with other histology,
such as thymic carcinoma, carcinoid or lymphoma, were excluded.
Each patient was required to fulfil the following criteria: 15–70
years of age; Eastern Cooperative Oncology Group (ECOG)
performance status, 0–2; and adequate organ function, that is,
leukocyte count X4000/ml, platelet count X10
5/ml, haemoglobin
X10.0g per 100ml, serum creatinine o1.5mg per 100ml,
creatinine clearance X60mlmin
 1, serum bilirubin o1.5mg per
100ml, serum alanine aminotransferase and aspartate amino-
transferase less than double the upper limit of the institutional
normal range, PaO2 X70mmHg and predicted post-operative
forced expiratory volume in 1s to be 50% or more of the age-,
sex- and height-predicted vital capacity. The exclusion criteria
included patients with uncontrolled heart disease, uncontrolled
diabetes or hypertension, pulmonary fibrosis or active pneumo-
nitis as evident on chest X-ray, infections necessitating systemic
use of antibiotics, disease necessitating emergency radiotherapy,
such as superior vena cava obstruction syndrome, active
concomitant malignancy, as well as pregnant or lactating women.
Also excluded were those with grave complications of thymoma,
such as pure red cell aplasia or hypogammaglobulinaemia;
myasthenia gravis was allowed and these patients were not
excluded per se.
Patient eligibility was confirmed by the JCOG Data Center before
patient registration. This study protocol was confirmed by the
JCOG protocol committee, and then approved by the institutional
review boards at each participating centre. Written informed
consent was obtained from all patients.
Treatment plan
Chemotherapy Patients received the 9-week CODE combination
chemotherapy described below. Each chemotherapeutic agent was
administered intravenously.
Week 1: CDDP 25mgm
 2 on day 1 with antiemetics and ample
hydration; VCR 1mgm
 2 on day 1; ADM 40mgm
 2 on day 1;
and ETP 80mgm
 2 on days 1–3.
Weeks 2, 4, 6 and 8: CDDP 25mgm
 2 on day 1 with antiemetics
and ample hydration and VCR 1mgm
 2 on day 1.
Weeks 3, 5, 7 and 9: CDDP 25mgm
 2 on day 1 with antiemetics
and ample hydration, ADM 40mgm
 2 on day 1 and ETP
80mgm
 2 on days 1–3.
Each week, G-CSF (filgrastim 50mgm
 2 per day or lenograstim
2mgkg
 1 per day) was administered by subcutaneous injection,
except on days when chemotherapy was administered or when the
leukocyte count was X10000/ml. Corticosteroid was used only as
part of the antiemetic regimen, and the specific drug and dosage
were not regulated by the protocol.
Dose and schedule modifications were carried out as previously
reported (Kunitoh et al, 2009).
Surgery and radiotherapy
When the tumour was clinically judged to be resectable by the
surgeons, radiologists and medical oncologists in each institution,
surgical resection of the tumour and a total thymectomy were
performed within 6 months (preferably within 3 months) after
completion of chemotherapy. For completely resected tumours,
post-operative thoracic radiotherapy up to 48Gy/24 fractions
was administered to the surgical margin and the mediastinum.
For incompletely resected or unresected tumours, thoracic radio-
therapy of up to 60Gy/30 fractions was administered to the
mediastinum and the residual tumour with 1.5-cm margins. The
radiation dose per fraction, 2Gy, and the total doses were
determined by the study group in view of previous reports (Girard
et al, 2009). The actual treatment delivery method was determined
at each institution.
Thoracic radiotherapy was started with a linear accelerator
(X4MeV) within 6 months of surgery or, for those who did not
undergo surgery, on completion of chemotherapy.
Patient evaluation and follow-up Before enrolment into the
study, each patient underwent a complete medical history and
physical examination (including neurological examination for
signs of myasthenia gravis), blood cell count determinations,
serum biochemistry testing, arterial blood gas analysis, pulmonary
function test, electrocardiogram, chest X-ray, computed tomo-
graphy (CT) scan of the chest, CT scan or ultrasound of the upper
abdomen, whole-brain CT or magnetic resonance imaging and an
isotope bone scan. Blood cell counts were determined, serum
biochemistry testing was carried out and chest X-rays were taken
weekly during each course of chemotherapy.
The toxicity of the chemotherapy was evaluated according to the
Japan Clinical Oncology Group Toxicity Criteria (Tobinai et al,
1993), modified from the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) version 1. Tumour responses
were assessed radiographically according to the standard, two-
dimensional WHO criteria (Miller et al, 1981) and classified into
complete response (CR), partial response (PR), no change (NC),
progressive disease (PD) and non-evaluable. Response confirma-
tion at 4 weeks or longer intervals was not required in the protocol.
After completion of the protocol therapy, the patients were
followed up with periodic re-evaluation, including chest CT every
6 months for the first 2 years and yearly thereafter.
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patients and their clinical responses were carried out at the time of
the study group meetings. The study coordinator (HK) and a few
selected investigators reviewed the radiographic films. The clinical
data presented below were all confirmed by this central review.
Reviews of pathological specimens were not carried out, because
the logistics of the study group were insufficient at the time of
study activation in 1997.
End points and statistical considerations
Because of the rarity of the tumour and the accrual to the US trials
(Loehrer et al, 1994, 1997), we presumed that we would be capable
of accruing 30 patients in the target accrual period of 4 years. The
sample size was, therefore, not based on statistical calculations.
The expected 5-year PFS rate was 60%, which would give a 95%
confidence interval of 40–77% with 30 cases.
Hence, the initial study design envisioned enrolment of 30 fully
eligible cases over 4 years, with a follow-up period of 5 years.
The secondary end points included toxicity and safety, objective
tumour response to chemotherapy, pattern of relapse, overall
survival (OS) and complete resection rate.
The PFS and OS were calculated from the date of enrolment and
estimated by the Kaplan–Meier method. Progression-free survival
was censored at the date verifiable to be progression free, and OS
was censored at the date of last follow-up. During the accrual
period, an interim analysis for futility was planned after half of the
patients were registered and followed up for at least 6 months. All
analyses were performed using SAS software version 8.2/9.1 (SAS
Institute, Cary, NC, USA).
RESULTS
Patient characteristics
A total of 23 patients from eight institutions were enrolled from
July 1997 to April 2005, when the study was terminated because of
slow accrual. Two patients were ineligible because of wrong
histology; one had thymic carcinoma, and the other had
lymphoma. These mistakes occurred because of technical pro-
blems in the patient registry. As the ineligible cases did receive the
protocol therapy, all 23 patients were analysed for characteristics
and toxicity. In all, 21 eligible patients were analysed for clinical
response, survival (PFS and OS) and surgical results. The patients’
characteristics are shown in Table 1. Diagnostic procedure was
CT-guided needle biopsy in most of the cases.
Reasons for surgical unresectability (one patient could have
more than one reason) included invasion into the following: the
pulmonary artery trunk in 10 cases, superior vena cava in 8, aorta
in 6, extensive pericardium or myocardium in 4, and sternum in 1.
Chemotherapy delivery and toxicity
Thirteen patients (57%) received the planned 9 weeks of
chemotherapy. The other 10 patients included 2 who received 8
weeks, 5 who received 7 weeks, 2 who received 6 weeks and 1 who
received 1 week of therapy. Reasons for ceasing chemotherapy
were patient refusal (six cases), attending doctors’ decision for
earlier local therapy (two cases), disease progression (one case)
and ineligibility (one case). The median duration of chemotherapy
for the 13 patients who underwent the planned 9 cycles was 9
weeks (range: 9–12 weeks). Among the nine patients who received
6–8 cycles, six received chemotherapy without delay and the
remaining three received chemotherapy with a delay of 1–4 weeks.
Table 2 summarises the major toxicities of the chemotherapy.
They were mainly haematological, and although about half of
the patients experienced grade 4 neutropenia, it was generally
transient and complicated by infection in only 1 case. Substantial
anaemia was frequently observed, consistent with other reports of
dose-dense CODE therapy (Fukuoka et al, 1997; Furuse et al,
1998). Overall, the toxicities were well tolerated. There were no
deaths related to toxicity.
Clinical response to induction therapy
The clinical responses of the 21 eligible patients to the
chemotherapy were judged radiologically and confirmed by central
review. The responses were as follows: CR, 0; PR, 13; NC, 7; and
PD, 1. The overall response rate was 62% (95% confidence interval:
38–82%).
Surgical and pathological results
Of the 21 eligible patients, a thoracotomy was performed in 13
(62%). Thoracotomy was performed 26–73 days (median: 47 days)
after completion of chemotherapy. The results of the surgery were
as follows: probe thoracotomy, two cases; gross residual tumour
(R2 resection), one case; microscopically residual tumour on
pathological review (R1 resection), one case; and complete surgical
and pathological resection (R0 resection), nine cases (43% of all
eligible cases). A combined resection of the adjunct organs
included pericardium in eight, lung parenchyma in eight, pleura
Table 1 Patients’ characteristics
Item Number
Sex (male/female) 17/6
Age, years (median/range) 56 (28–70)
ECOG performance status
PS0/PS1/PS2 9/14/0
Smoking history
No 13
Yes (median pack-years) 10 (28)
Myasthenia gravis (no/yes) 21/2
Histology: thymoma and eligible 21
Lymphocyte predominance 10
Mixed cell 4
Epithelioid cell 6
Spindle cell 1
Histology: not thymoma (ineligible) 2
Carcinoma 1
Lymphoma 1
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; PS¼performance
status.
Table 2 Toxicity of the chemotherapy (N¼23)
Toxicity Grades 1/2 Grade 3 Grade 4 %Grade 3/4
Leukopenia 4/5 8 5 57
Neutropenia 1/6 3 11 61
Anaemia 0/3 19 ND 83
Thrombocytopenia 6/4 4 2 26
ALT 10/1 1 0 4
Creatinine 2/0 0 0 0
PaO2 5/6 0 0 0
Emesis 10/8 3 ND 13
Diarrhea 3/3 1 0 4
Stomatitis 5/2 0 0 0
Constipation 2/1 0 0 0
Neuropathy 7/2 0 ND 0
Infection 5/2 3 0 13
Abbreviations: ALT¼alanine aminotransaminase; ND¼not defined (the Japan
Clinical Oncology Group toxicity criteria did not define grade 4 in these toxicities).
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and others in five cases. Pathological CR (pCR), with no residual
viable tumour cells in resected specimens, was achieved in three
patients (14% of the 21 eligible patients).
The major post-operative morbidities included one case of
pulmonary infarction, which subsequently recovered.
Boost radiotherapy
Post-operative radiotherapy was administered to 7 of the 13
patients who underwent thoracotomy: four of the nine patients
with R0 resection received radiotherapy of 48, 48, 48 and 8Gy,
respectively; one of the two patients with incomplete resection
received radiotherapy of 50Gy; and each of the two patients with
probe thoracotomy received radiotherapy of 60Gy. Reasons for
not carrying out radiotherapy included surgery-related complica-
tion or incomplete recovery (three cases), disease progression (two
cases) and patient refusal (one case). Of the eight patients without
thoracotomy, five received radiotherapy, with a dose of 60Gy for
each case. The other three patients refused radiotherapy.
The study schema with the actual numbers of patients receiving
the protocol therapy is shown in Figure 1.
Other and late complications
Thirteen patients received thoracic radiotherapy. The toxicities
were generally mild and manageable. There were four patients with
grade 2 oesophagitis, one patient with a grade 3 skin reaction and
another with a grade 2 skin reaction. All other adverse events were
grade 0 or 1.
One patient was reported to have pure red cell aplasia, which
occurred while receiving post-operative radiotherapy. Radio-
therapy was terminated, and the patient recovered with immuno-
suppressant therapy.
Progression-free and overall survival
Survival data were last updated in May 2009, 4 years after accrual
of the last patient. Figure 2 shows the PFS and OS curves for the
21 eligible cases. The median PFS was 4.5 years (95% confidence
interval: 2.3 not calculable years), and the PFS at 2, 5 and 8 years
was 80, 43 (95% confidence interval: 21–63%) and 32%,
respectively. The median OS was not reached, and the OS at 2, 5
and 8 years was 100, 85 (95% confidence interval: 61–95%) and
69%, respectively.
Of the 21 eligible patients, 11 underwent surgical resection (nine
complete resection and two incomplete resection), whereas 10 did
not (including two who underwent a probe thoracotomy). The PFS
and OS were quite similar for those with or without surgical
resection. The 5- and 8-year PFS rates for those who underwent
resection were 46 and 36% for those with surgical resection and 39
and 26% for those without, respectively (Figure 3). The 5- and
8-year OS rates were 91 and 73% for those with surgical resection
and 79 and 63% for those without, respectively (Figure 4).
For the nine patients who underwent R0 resection, the outcomes
were marginally better, with 5- and 8-year PFS rates of 56 and
44%, respectively, and 5- and 8-year OS rates of 89 and 78%,
respectively. The case with R1 resection had relapse at 2.3 years,
and the case with R2 resection had relapse at 0.7 year.
All three patients who achieved pCR were alive and disease free
at 6.3–7.4 years of follow-up.
Pattern of relapse
So far, 13 of the 21 eligible patients have had tumour relapse. All of
the 13 relapsed patients initially demonstrated regrowth of the
primary and/or pleural or pericardial dissemination: primary only
Enrollment: 23
Eligible&Cx: 21
Surgery: 13
R0 resection: 9
No RT: 5 RT: 4 Incomplete
RT in 1
RT: 3
No RT: 1
No RT: 3
No surgery: 8
Ineligible: 2
Incomplete: 4
RT: 5
Figure 1 Study schema of the Japan Clinical Oncology Group (JCOG)
9606 trial, with the number of patients who actually received each of the
protocol therapies. Cx, chemotherapy; RT, radiotherapy.
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Figure 2 Progression-free survival (PFS) and overall survival (OS) of the
21 eligible patients.
P
r
o
p
o
r
t
i
o
n
 
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
With resection (n=11)
Without resection (n=10)
Year
0123456789 1 0 1 1
Figure 3 Progression-free survival of the 21 eligible patients, according
to the surgery undergone. Resection was performed in 11 patients
(complete resection in nine), and 10 patients did not undergo resection
(including two with probe thoracotomy). There was no significant
difference (log rank P¼0.75).
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sin five; pleura or pericardium only in six, and both in two2. None
had initial relapse involving distant organs. There was no report of
needle biopsy-track recurrence.
DISCUSSION
The optimal management of unresectable stage III thymoma
remains unclear. There are some reports of combined modality
approaches including chemotherapy and surgery, but many
reports included stage IV disease and/or thymic carcinoma
histology (Berruti et al, 1999; Kim et al, 2004; Lucchi et al, 2006;
Yokoi et al, 2007). Reports of multicentre prospective trials are
very few (Table 3).
In the current trial, we prospectively accrued patients with
unresectable stage III thymoma, and excluded thymic carcinoma;
it is now evident that thymoma and thymic carcinoma differ in
clinical presentation and in prognosis, and trials on them should
be reported separately (Eng et al, 2004; Giaccone, 2005).
We previously reported the results of another trial, JCOG 9605
(Kunitoh et al, 2009), in which we treated patients with stage IV
thymoma with CODE chemotherapy. The results were similar to
conventional chemotherapy, and we concluded that intensive
chemotherapy does not seem to be promising enough in
disseminated thymoma. However, dose-dense chemotherapy
might still have a role in patients with limited tumour burden, in
combination with definitive local therapy.
Although our results showed that CODE chemotherapy in
combination with local therapy could be safely administered to
thymoma patients, the efficacy was not remarkable. Compliance
to chemotherapy was poorer; only 57% of patients completed the
planned 9-week schedule, as compared with the 87% rate in the
JCOG 9605 study for stage IV disease (Kunitoh et al, 2009).
Doctors’ and patients’ decisions were the main reasons for ceasing
chemotherapy and early local therapy. Therefore, although
chemotherapy itself was well tolerated, toxicities such as malaise
or fatigue, which the old JCOG toxicity criteria did not define,
might have compromised the completion of chemotherapy before
surgery.
Moreover, although the sample size was smaller than expected
because of poor accrual, the 5-year PFS rate was 43% (95%
confidence interval: 21–63%), which fell short of the expected
60%. Although the OS rate was favourable, it would be difficult
to make a valid conclusion because of the small sample size
(Table 3).
In this study, we did show that about half of the patients with an
initially unresectable thymoma were able to undergo complete
resection after induction CODE chemotherapy. However, both PFS
and OS were surprisingly similar for patients with and without
complete resection.
Those who underwent complete resection got numerically better
PFS and OS rates, but the difference with unresected cases was
marginal, especially considering the selection bias. Only those who
received pathological CR enjoyed clearly favourable outcomes.
Low compliance to radiotherapy in patients with surgery could
partly account for the unexpected results.
Complete resection has been reported to be associated with good
prognosis in patients with stage III thymoma (Regnard et al, 1996;
Girard et al, 2009). On the other hand, the role of ‘debulking’
surgery, in patients in whom complete resection is not feasible,
remains unclear. Although some have suggested it to be beneficial
(Liu et al, 2006), others reported that it could not affect the
outcome as compared with biopsy only, followed by radiotherapy
(Ciernik et al, 1994).
Taken together with our results, we believe that the role of
surgery in locally advanced thymoma, as compared with definitive
radiotherapy, still remains to be established, especially in
combination with systemic chemotherapy. More studies are
warranted.
One major limitation of the study is that we did not perform a
central review of the histology, and thus could not provide WHO
classifications of histology (Okumura et al, 2002; Travis et al,
2004). This makes comparisons with results from other reports
difficult. Central pathology review and, preferably, tissue collection
would be very important in future trials.
Now JCOG is discussing our next study on thymoma. As
intensification of the current chemotherapy does not seem to
be promising enough, our next approach would be trials with
new agents, cytotoxic (such as amrubicin or irinotecan) or target
based. More translational research of the tumour would be
necessary, as well as international cooperation, given the rarity
of the disease.
In conclusion, we found that weekly dose-dense chemotherapy
could be administered safely to patients with thymoma, even when
combined with local therapy in localised disease. However, the
efficacy seemed to be no better than that of conventional
chemotherapy. More research on the optimal systemic therapy,
as well as on the role of surgery in locally advanced disease, seems
to be necessary.
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Table 3 Reports of prospective trials of combined modality therapy for
locally advanced thymoma
Treatment Stage Patients
a ORR 5-yr OS
PAC, R (Loehrer et al, 1997) III 23 70% 52.5%
b
PAC, S, R (Kim et al, 2004) III/IV 22 77% 95%
c
CODE, S, R (current study) III 21 62% 85%
d
Abbreviations: CODE¼combination chemotherapy with cisplatin/vincristine/doxo-
rubicin/etoposide; ORR: overall response rate; PAC¼combination chemotherapy
with cisplatin/doxorubicin/cyclophosphamide; R¼thoracic radiotherapy; S¼surgical
resection; 5-yr OS¼overall survival rate at 5 years.
aNumber of assessable patients.
bIncluding patients with thymic carcinoma.
c7-year OS rate was 79%.
d8-year OS rate
was 69%.
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